NCT01597388 2026-02-24AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerAstraZenecaPhase 1 Completed99 enrolled 61 charts
NCT02208375 2025-12-31mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianM.D. Anderson Cancer CenterPhase 1 Active not recruiting159 enrolled